ADC Therapeutics SA logo

ADC Therapeutics SANYSE: ADCT

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

Switzerland

IPO:

18 May 2020

Next earnings report:

13 March 2025

Last dividends:

N/A

Next dividends:

N/A
$189.51 M
-89%vs. 3y high
53%vs. sector
-vs. 3y high
-vs. sector
-111%vs. 3y high
10%vs. sector
-97%vs. 3y high
45%vs. sector

Price

after hours | Wed, 20 Nov 2024 22:46:13 GMT
$1.96-$0.18(-8.41%)

Dividend

No data over the past 3 years
$18.46 M$18.82 M
$18.46 M-$43.97 M

Analysts recommendations

Institutional Ownership

ADCT Latest News

ADC Therapeutics SA (ADCT) Q3 2024 Earnings Call Transcript
seekingalpha.com09 November 2024 Sentiment: NEUTRAL

ADC Therapeutics SA (NYSE:ADCT ) Q3 2024 Results Conference Call November 7, 2024 8:30 AM ET Company Participants Marcy Graham - Investor Relations Ameet Mallik - Chief Executive Officer Pepe Carmona - Chief Financial Officer Lindsay Drucker Mann - Global Chief Financial Officer Conference Call Participants Michael Schmidt - Guggenheim Eric Schmidt - Cantor Fitzgerald Kelly Shi - Jefferies Operator Good morning, ladies and gentlemen, and welcome to the ADC Therapeutics Third Quarter 2024 Earnings Conference Call. [Operator Instructions] This call is being recorded on Thursday, November 7, 2024.

ADC Therapeutics SA (ADCT) Reports Q3 Loss, Lags Revenue Estimates
zacks.com07 November 2024 Sentiment: NEGATIVE

ADC Therapeutics SA (ADCT) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to loss of $0.58 per share a year ago.

Is ADC Therapeutics (ADCT) Stock Outpacing Its Medical Peers This Year?
zacks.com01 November 2024 Sentiment: NEUTRAL

Here is how ADC Therapeutics SA (ADCT) and Agios Pharmaceuticals (AGIO) have performed compared to their sector so far this year.

ADC Therapeutics SA (ADCT) Q2 2024 Earnings Call Transcript
seekingalpha.com11 August 2024 Sentiment: NEUTRAL

Start Time: 08:30 January 1, 0000 9:04 AM ET ADC Therapeutics SA (NYSE:ADCT ) Q2 2024 Earnings Conference Call August 06, 2024, 08:30 AM ET Company Participants Ameet Mallik - CEO Jose Carmona - CFO Marcy Graham - IRO Conference Call Participants Eric Schmidt - Cantor Fitzgerald Kelly Shi - Jefferies Michael Schmidt - Guggenheim Brian Cheng - JPMorgan Operator Welcome to the ADC Therapeutics Second Quarter 2024 Financial Results Conference Call. My name is Didi, and I will be your operator for today's call.

ADC Therapeutics SA (ADCT) Reports Q2 Loss, Lags Revenue Estimates
zacks.com06 August 2024 Sentiment: NEUTRAL

ADC Therapeutics SA (ADCT) came out with a quarterly loss of $0.38 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to loss of $0.58 per share a year ago.

Stocks to Buy: 3 Biotech Bargains Delivering Breakthroughs on a Budget
investorplace.com13 June 2024 Sentiment: POSITIVE

Fundamentally, biotech stocks to buy operate on a clear and unavoidable narrative: wealth means nothing without health. You hear various stories about extremely wealthy tycoons throwing all kinds of money, not just for lifesaving procedures but in more superficial efforts such as maintaining youth and vitality.

ADC Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
GlobeNewsWire15 May 2024 Sentiment: POSITIVE

ADC Therapeutics SA (NYSE: ADCT) has revealed that Ameet Mallik, the Chief Executive Officer, will be taking part in a fireside chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ on May 20, 2024 at 2:00 p.m. ET.

ADC Therapeutics SA (ADCT) Reports Q1 Loss, Misses Revenue Estimates
Zacks Investment Research06 May 2024 Sentiment: NEGATIVE

ADC Therapeutics SA (ADCT) reported a quarterly loss of $0.56 per share, which was in line with the Zacks Consensus Estimate. This is an improvement from the loss of $0.74 per share reported in the same quarter last year.

ADC Therapeutics SA (ADCT) Reports Q4 Loss, Tops Revenue Estimates
Zacks Investment Research13 March 2024 Sentiment: NEGATIVE

ADC Therapeutics SA (ADCT) came out with a quarterly loss of $1.03 per share versus the Zacks Consensus Estimate of a loss of $0.47. This compares to loss of $0.30 per share a year ago.

Earnings Preview: ADC Therapeutics SA (ADCT) Q4 Earnings Expected to Decline
Zacks Investment Research20 February 2024 Sentiment: NEGATIVE

ADC Therapeutics SA (ADCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • 1(current)

What type of business is ADC Therapeutics SA?

ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound, ADCT-602 that is in a Phase 1/2 investigator-initiated study in relapsed or refractory B-cell acute lymphoblastic leukemia. Further, its clinical-stage pipeline consists of ADCT-601 (mipasetamab uzoptirine) targeting AXL as a single agent and/or in combination in sarcoma, pancreatic, and NSCLC, as well as pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, and other undisclosed targets. The company was incorporated in 2011 and is headquartered in Epalinges, Switzerland.

What sector is ADC Therapeutics SA in?

ADC Therapeutics SA is in the Healthcare sector

What industry is ADC Therapeutics SA in?

ADC Therapeutics SA is in the Biotechnology industry

What country is ADC Therapeutics SA from?

ADC Therapeutics SA is headquartered in Switzerland

When did ADC Therapeutics SA go public?

ADC Therapeutics SA initial public offering (IPO) was on 18 May 2020

What is ADC Therapeutics SA website?

https://www.adctherapeutics.com

Is ADC Therapeutics SA in the S&P 500?

No, ADC Therapeutics SA is not included in the S&P 500 index

Is ADC Therapeutics SA in the NASDAQ 100?

No, ADC Therapeutics SA is not included in the NASDAQ 100 index

Is ADC Therapeutics SA in the Dow Jones?

No, ADC Therapeutics SA is not included in the Dow Jones index

When was ADC Therapeutics SA the previous earnings report?

No data

When does ADC Therapeutics SA earnings report?

The next expected earnings date for ADC Therapeutics SA is 13 March 2025